Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1

Interventions

Rituximab 12Biopsy 12Specimen Handling 11Cyclophosphamide 11Magnetic Resonance Spectroscopy 10obinutuzumab 7Lenalidomide 7fludarabine 6Prednisone 6pembrolizumab 5Nuclear Medicine Department, Hospital 5X-Rays 4Doxorubicin 4venetoclax 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3GSK2636771 3Etoposide 3Busulfan 3Bendamustine Hydrochloride 3zanubrutinib 2trametinib 2tocilizumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × eflapegrastim × 30 days × Clear all
NCT04570423 2026-05-22

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Spectrum Pharmaceuticals, Inc

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡